Grant Holder |
Researcher |
Completed project Institute Amount Awarded Duration Type of Award |
Title
The role of ER/AP-1 activation in endocrine resistant human breast cancer
Synopsis
Many patients relapse on treatment with endocrine (hormone) agents such as tamoxifen because their tumours develop resistance. This research will help understand why, and may determine whether new treatments can overcome or prevent such resistance.
Aims & Goals
While tamoxifen is an important treatment for oestrogen receptor positive breast cancer, some tumours do not respond while others develop resistance over time. We are beginning to understand how this occurs, which may allow us to develop more effective hormone treatment.
Publications
| Title | The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling |
| Year | 2005 |
| Authors | L-A Martin, S Pancholi, C M W Chan, I Farmer, C Kimberley, M Dowsett and S R D Johnston |
Presentations
| Title | Change in ligand-dependent growth and ERE/AP-1 gene transcription in endocrine resistant breast cancer. |
| Year | 2001 |
| Authors | Christina CMW Chan, Anne E Lykkesfeldt, Stephen RD Johnston, Institute of Cancer Research, Academic Biochemistry, London, UK; Danish Cancer Society, Copenhagen, Denmark; Royal Marsden Hospital, Department of Medicine, London, UK |
